REG - Hikma Pharmaceutical - Annual Information Update <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

07/04/2016 11:45

RNS Number : 5115U
Hikma Pharmaceuticals Plc
07 April 2016
Hikma Pharmaceuticals PLC
Annual Information Update
London, 7 April 2016. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date 
Headline 
07/04/2016
Annual Financial Report
06/04/2016
Blocklisting Interim Review
05/04/2016
Director/PDMR Shareholding
31/03/2016
Director/PDMR Shareholding
29/03/2016
Director/PDMR Shareholding
21/03/2016
Director/PDMR Shareholding
17/03/2016
Director/PDMR Shareholding
16/03/2016
Final Results
03/03/2016
Notice of Results
29/02/2016
Holding(s) in Company
29/02/2016
Holding(s) in Company
29/02/2016
Total Voting Rights
29/02/2016
Roxane Acquisition Close
22/02/2016
Directorate Change
19/02/2016
EGM Statement
11/02/2016
Holding(s) in Company
11/02/2016
Circ re. Roxane Acquisition
10/02/2016
Circ re. Roxane Acquisition
22/01/2016
Circ re. Roxane Acquisition and EGM
07/01/2016
Total Voting Rights
24/12/2015
Shareholders' Agreement and Board Appointment
17/12/2015
Total Voting Rights
03/12/2015
Director/PDMR Shareholding
25/11/2015
Hikma announces sale of Ben Venue manufacturing
24/11/2015
Holding(s) in Company
18/11/2015
Resolution to FDA Warning Letter
16/11/2015
Holding(s) in Company
11/11/2015
Holding(s) in Company
10/11/2015
Holding(s) in Company
02/11/2015
Trading Statement
22/10/2015
Block Listing of Share
19/10/2015
Holding(s) in Company
12/10/2015
Blocklisting Interim Review
08/10/2015
Total Voting Rights
18/09/2015
Audit Tender
16/09/2015
Total Voting Rights
11/09/2015
Director/PDMR Shareholding
27/08/2015
Director/PDMR Shareholding
27/08/2015
Director/PDMR Shareholding
19/08/2015
Director/PDMR Shareholding
19/08/2015
Interim Results
28/07/2015
Acquisition
14/07/2015
Total Voting Rights
18/05/2015
Director/PDMR Shareholding
15/05/2015
Director/PDMR Shareholding
14/05/2015
Result of AGM
14/05/2015
AGM Trading Update
15/04/2015
Holding(s) in Company
10/04/2015
Total Voting Rights
10/04/2015
Director/PDMR Shareholding
09/04/2015
Annual Information Update
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 
Documents filed with the Financial Conduct Authority
The Company has filed the following documents with the Financial Conduct Authority ("FCA") via the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.door at the Company's registered office.
Date
Document
07/04/2016
Annual Report and Accounts 2015
07/04/2016
Notice of 2016 Annual General Meeting 
07/04/2016
Proxy form for the 2016 Annual General Meeting
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 
Date Filed
Form
Description
02/03/2016
AP01
Appointment of John Julius Castellani as a director on 1 March 2016
29/02/2016
SH01
Statement of capital following an allotment of shares on 29 February 2016
29/02/2016
AP01
Appointment of Jochen Gann as a director on 29 February 2016
07/01/2016
SH01
Statement of capital following an allotment of shares on 7 January 2016
17/12/2015
SH01
Statement of capital following an allotment of shares on 16 December 2015
09/10/2015
SH01
Statement of capital following an allotment of shares on 9 October 2015
17/09/2015
SH01
Statement of capital following an allotment of shares on 17 September 2015
11/09/2015
AR01
Annual return made up to 7 September 2015 no member list
09/09/2015
SH01
Statement of capital following an allotment of shares on 19 August 2015
15/07/2015
SH01
Statement of capital following an allotment of shares on 13 July 2015
10/06/2015
AA
Group of companies' accounts made up to 31 December 2014
29/05/2015
RESOLUTIONS
RES09 - Resolution of authority to purchase a number of shares
RES10 - Resolution of allotment of securities
RES10 - Resolution of allotment of securities
07/04/2015
SH01
Statement of capital following an allotment of shares on 31 March 2015
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk. 
Documents provided to Shareholders
Further Information
Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW. 
Peter Speirs
Company Secretary
7 April 2016
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCBDLFBQZFZBBB